When consolidating de novo oligometastatic NSCLC with initial hilar nodal involvement, would you still include the hilum if that disease completely responded to induction chemotherapy?

If the patient had oligo-met before induction chemotherapy, I would consider to TX all previously involved sites. However, if the patient has oligo-met after induction chemotherapy but had poly-met before chemotherapy, I would only TX active residual disease.